Phase II study of the tetrahydropyranyl adriamycin--cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma

被引：26

作者：

Kasahara, Senji ^{[1
]}

Hara, Takeshi ^{[1
]}

Tsurumi, Hisashi ^{[1
]}

Goto, Naoe ^{[1
]}

Kitagawa, Jun-Ichi ^{[2
]}

Kanemura, Nobuhiro ^{[1
]}

Yoshikawa, Takeshi ^{[1
]}

Goto, Hideko ^{[3
]}

Fukuno, Kenji ^{[4
]}

Yamada, Toshiki ^{[1
]}

Sawada, Michio ^{[2
]}

Takahashi, Takeshi ^{[4
]}

Takami, Tsuyoshi ^{[5
]}

Moriwaki, Hisataka ^{[1
]}

机构：

[1] Gifu Univ, Grad Sch Med, Dept Internal Med 1, Gifu 5011194, Japan

[2] Gifu Red Cross Hosp, Dept Hematol, Gifu, Japan

[3] Kisogawa Municipal Hosp, Dept Internal Med, Kisogawa, Japan

[4] Gifu Municipal Hosp, Div Hematol, Gifu, Japan

[5] Gifu Univ, Grad Sch Med, Dept Immunopathol, Gifu 5011194, Japan

来源：

LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 04期

关键词：

R-CHOP; R-THP-COP; non-Hodgkin lymphoma; pirarubicin; elderly; NON-HODGKINS-LYMPHOMA; COLONY-STIMULATING FACTOR; THP-COP; CHOP; CHEMOTHERAPY; PIRARUBICIN; TRIAL; DOXORUBICIN; THERAPY; CSF;

D O I：

10.3109/10428194.2011.555024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The anthracycline drug pirarubicin (tetrahydropyranyl adriamycin; THP) apparently has fewer cardiotoxic effects than doxorubicin. We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL). However, that study was completed before rituximab (R) was introduced into clinical practice. Here we report a phase II study of the THP-COP regimen combined with R (R-THP-COP) every 3 weeks. The complete response and 3-year overall survival rates was 63%% and 53%%, respectively, and no deaths were related to the regimen. We conclude that the R-THP-COP regimen is safe and effective for patients with DLBCL. Based on these results, a randomized controlled trial of rituximab--cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) and R-THP-COP as a phase III study is ongoing.</.

引用

页码：629 / 634

页数：6

共 30 条

[21] Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study [J].

Pfreundschuh, Michael ;

Ho, Anthony D. ;

Covallin-Stahl, Eva ;

Wolf, Max ;

Pettengell, Ruth ;

Vasova, Ingrid ;

Belch, Andrew ;

Walewski, Jan ;

Zinzani, Pier-Luigi ;

Mingrone, Walter ;

Kvaloy, Stein ;

Shpilberg, Ofer ;

Jaeger, Ulrich ;

Hansen, Mads ;

Corrado, Claudia ;

Scheliga, Adriano ;

Loeffler, Markus ;

Kuhnt, Evelyn .

LANCET ONCOLOGY, 2008, 9 (05) :435-444

[22] Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60) [J].

Pfreundschuh, Michael ;

Schubert, Joerg ;

Ziepert, Marita ;

Schmits, Rudolf ;

Mohren, Martin ;

Lengfelder, Eva ;

Reiser, Marcel ;

Nickenig, Christina ;

Clemens, Michael ;

Peter, Norma ;

Bokemeyer, Carsten ;

Eimermacher, Hartmut ;

Ho, Anthony ;

Hoffmann, Martin ;

Mertelsmann, Roland ;

Truemper, Lorenz ;

Balleisen, Leopold ;

Liersch, Ruediger ;

Metzner, Bernd ;

Hartmann, Frank ;

Glass, Bertram ;

Poeschel, Viola ;

Schmitz, Norbert ;

Ruebe, Christian ;

Feller, Alfred C. ;

Loeffler, Markus .

LANCET ONCOLOGY, 2008, 9 (02) :105-116

[23] A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy [J].

Sawada, M ;

Tsurumi, H ;

Yamada, T ;

Hara, T ;

Fukuno, K ;

Goto, H ;

Shimizu, M ;

Kasahara, S ;

Yoshikawa, T ;

Kanemura, N ;

Oyama, M ;

Takami, T ;

Moriwaki, H .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 68 (06) :354-361

[24] The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP [J].

Sehn, Laurie H. ;

Berry, Brian ;

Chhanabhai, Mukesh ;

Fitzgerald, Catherine ;

Gill, Karamjit ;

Hoskins, Paul ;

Klasa, Richard ;

Savage, Kerry J. ;

Shenkier, Tamara ;

Sutherland, Judy ;

Gascoyne, Randy D. ;

Connors, Joseph M. .

BLOOD, 2007, 109 (05) :1857-1861

[25]

SIMON R, 1987, CANCER TREAT REP, V71, P1079

[26]

TAKAGI T, 1987, CANCER CHEMOTH PHARM, V20, P151

[27] Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma - A comparison of doxorubicin and pirarubicin: a randomized phase II study [J].

Tsurumi, H ;

Yamada, T ;

Sawada, M ;

Kasahara, S ;

Kanemura, N ;

Kojima, Y ;

Fukuno, K ;

Hara, T ;

Saio, M ;

Takahashi, T ;

Oyama, M ;

Ozawa, K ;

Takami, T ;

Moriwaki, H .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (02) :107-113

[28] A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma [J].

Tsurumi, Hisashi ;

Hara, Takeshi ;

Goto, Naoe ;

Kanemura, Nobuhiro ;

Kasahara, Senji ;

Sawada, Michio ;

Yasuda, Ichiro ;

Yamada, Toshiki ;

Shimizu, Masahito ;

Takami, Tsuyoshi ;

Moriwaki, Hisataka .

HEMATOLOGICAL ONCOLOGY, 2007, 25 (03) :107-114

[29] TETRAHYDROPYRANYL DERIVATIVES OF DAUNOMYCIN AND ADRIAMYCIN [J].

UMEZAWA, H ;

TAKAHASHI, Y ;

KINOSHITA, M ;

NAGANAWA, H ;

MASUDA, T ;

ISHIZUKA, M ;

TATSUTA, K ;

TAKEUCHI, T .

JOURNAL OF ANTIBIOTICS, 1979, 32 (10) :1082-1084

[30] THE IMPORTANCE OF AGE IN SURVIVAL OF PATIENTS TREATED WITH CHEMOTHERAPY FOR AGGRESSIVE NON-HODGKINS LYMPHOMA [J].

VOSE, JM ;

ARMITAGE, JO ;

WEISENBURGER, DD ;

BIERMAN, PJ ;

SORENSEN, S ;

HUTCHINS, M ;

MORAVEC, DF ;

HOWE, D ;

DOWLING, MD ;

MAILLIARD, J ;

JOHNSON, PS ;

PEVNICK, W ;

PACKARD, WM ;

OKERBLOOM, J ;

THOMPSON, RF ;

LANGDON, RM ;

SOORI, G ;

PETERSON, C .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1838-1844

← 1 2 3 →